Research map: AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance

Back to the article

Papers in this map

  1. Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis · James J. Sejvar · 2011 · 967 citations · Cited by this paper
  2. Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group · 2026 · Related
  3. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults · Alberto A. Papi · 2023 · 793 citations · Cited by this paper
  4. A Large Language Model for Extracting Post-marketing Adverse Drug Events from Clinical Notes in the Electronic Health Record · 2026 · Related
  5. Respiratory syncytial virus infection in adults · Hannah H. Nam · 2019 · 340 citations · Cited by this paper
  6. Pharmacovigilance Through Fresh Eyes: The International Society of Pharmacovigilance Student Community's Role in Shaping the Future of Pharmacovigilance · 2026 · Related
  7. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 · Michael Melgar · 2023 · 336 citations · Cited by this paper
  8. Reliability of Self-Reported Maternal Health and Mother–Infant Outcome Data in Web-Based Questionnaires · 2026 · Related
  9. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future · Muaed Jamal Alomar · 2020 · 273 citations · Cited by this paper
  10. Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant · 2026 · Related
  11. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020 · Angela R Branche · 2021 · 264 citations · Cited by this paper
  12. MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases · 2025 · Related
  13. Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis · John M. McLaughlin · 2022 · 235 citations · Cited by this paper
  14. Pharmacovigilance Due Diligence in Drug Development: A Practical Playbook for Risk Identification, Compliance Assessment, and Strategic Decision Making · 2025 · Related
  15. Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem · Angela R Branche · 2015 · 210 citations · Cited by this paper
  16. US Risk Evaluation and Mitigation Strategies with Elements to Assure Safe Use: A Longitudinal Analysis of REMS Modifications (2008–2022) · 2026 · Related
  17. Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis · Chukwuemeka Onwuchekwa · 2023 · 208 citations · Cited by this paper
  18. GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands · 2025 · Related
  19. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons · Michael G. Ison · 2024 · 176 citations · Cited by this paper
  20. Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center · 2026 · Related
  21. Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study · You Li · 2023 · 162 citations · Cited by this paper
  22. RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes · Ilse Dieussaert · 2024 · 136 citations · Cited by this paper
  23. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis · Amanda B. Payne · 2024 · 132 citations · Cited by this paper
  24. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial · Isabel Leroux‐Roels · 2022 · 124 citations · Cited by this paper
  25. Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT–PCR · Julio A. Ramírez · 2023 · 110 citations · Cited by this paper
  26. Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018 · Brent A. Williams · 2020 · 108 citations · Cited by this paper
  27. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000–2013 · Beth F. Hibbs · 2015 · 80 citations · Cited by this paper
  28. Monitoring product safety in the postmarketing environment · Robert G. Sharrar · 2013 · 79 citations · Cited by this paper
  29. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial · Michael G. Ison · 2025 · 70 citations · Cited by this paper
  30. The recent landscape of RSV vaccine research · Karen J Kelleher · 2025 · 64 citations · Cited by this paper
  31. Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older · Sarah E. Fry · 2025 · 63 citations · Cited by this paper
  32. Pharmacoepidemiological considerations in observed‐to‐expected analyses for vaccines · Olivia Mahaux · 2015 · 62 citations · Cited by this paper
  33. Anaphylaxis: Revision of the Brighton collaboration case definition · Michael Gold · 2022 · 62 citations · Cited by this paper
  34. Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions · Robert G. Feldman · 2023 · 56 citations · Cited by this paper
  35. Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease · Sara Yee Tartof · 2024 · 46 citations · Cited by this paper
  36. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons · Diya Surie · 2025 · 44 citations · Cited by this paper
  37. Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines · Cleo G. Anastassopoulou · 2025 · 43 citations · Cited by this paper
  38. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial · Tino F. Schwarz · 2023 · 41 citations · Cited by this paper
  39. Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024 · Anne M. Hause · 2024 · 40 citations · Cited by this paper

Source: OpenAlex (CC0)